Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Reply to “Evaluation of nanomedicines: stick to the basics”

Nature Reviews Materials volume 1, Article number: 16074 (2016) Cite this article

McNeil has captured the main criticism of our Perspective article (Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016))1 in his Correspondence (Evaluation of nanomedicines: stick to the basics. Nat.Rev.Mater.http://dx.doi.org/10.1038/natrevmats.2016.73(2016))2. A major flaw of his argument is associated with the number of clinical studies. McNeil's “empirical evidence” suggests that there are “over 500 clinical studies, with nearly 25% of those in phase III trials”. At first sight, these numbers are impressive and might indicate that significant clinical translation and the success of cancer nanomedicine developments are a reality.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: Analysis of studies in clinical trial phases.

References

  1. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).

    CAS  Article  Google Scholar 

  2. McNeil, S. Correspondence to the editor. Nat. Rev. Mater. http://dx.doi.org/10.1038/natrevmats.2016.73 (2016).

  3. Petersen, G. H., Alzghari, S. K., Chee, W., Sankari, S. S. & La-Beck, N. M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J. Control. Release 232, 255–264 (2016).

    CAS  Article  Google Scholar 

  4. [No authors listed.] A billion dollar punt. Nat. Biotechnol. 24, 1453 (2006).

  5. Carroll, J. Merck writes off RNAi, punts Sirna to Alnylam for $175M. FierceBiotechhttp://www.fiercebiotech.com/financials/merck-writes-off-rnai-punts-sirna-to-alnylam-for-175m (updated 4 Jul 2016).

  6. Brunton, L. L., Chabner, B. & Knollmann, B. C. Goodman & Gilman's the Pharmacological Basis of Therapeutics (McGraw-Hill Medical, 2011).

    Google Scholar 

  7. Sykes, E. A. et al. Tailoring nanoparticle designs to target cancer based on tumor pathophysiology. Proc. Natl Acad. Sci. USA 113, E1142–E1151 (2016).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stefan Wilhelm, Anthony J. Tavares and Warren C. W. Chan are at the Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College St, Toronto, Ontario, M5S 3G9, Canada.,

    Stefan Wilhelm, Anthony J. Tavares & Warren C. W. Chan

  2. Warren C. W. Chan is at the Donnelly Center for Cellular and Biomolecular Research, University of Toronto, 160 College St, Toronto, Ontario, M5S 3E1, Canada.,

    Warren C. W. Chan

  3. Departments of Chemistry, Materials Science and Engineering, and Chemical Engineering, University of Toronto, 164 College St, Toronto, M5S 3G9, Ontario, Canada

    Warren C. W. Chan

Authors
  1. Stefan Wilhelm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony J. Tavares
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Warren C. W. Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Warren C. W. Chan.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Supplementary information S1–S3 (box, figure, table)

Supplementary information (PDF 302 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wilhelm, S., Tavares, A. & Chan, W. Reply to “Evaluation of nanomedicines: stick to the basics”. Nat Rev Mater 1, 16074 (2016). https://doi.org/10.1038/natrevmats.2016.74

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/natrevmats.2016.74

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing